Fingolimod for the treatment of primary-progressive multiple sclerosis
Following on from advice received from the company, there are no further plans to continue the development programme for fingolimod in primary-progressive multiple sclerosis. Therefore, NICE has decided to suspend this appraisal from its work programme. As this appraisal has been referred to the Institute we will continue to monitor any development and will update interested parties if the situation changes.
 
Status Suspended
Process STA
Referral date 01 November 2008
Topic area
  • Central nervous system

Provisional Schedule

Closing date for invited submissions / evidence submission: TBC
1st appraisal committee meeting: TBC

Project Team

Communications manager: Paul Cooney
Executive Lead: TBC
Project manager: Jeremy Powell
Technical Lead: TBC

Timeline

Key events during the development of the guidance:

Date Update
08 October 2015 Suspended, Following on from advice received from the company, there are no further plans to continue the development programme for fingolimod in primary-progressive multiple sclerosis. Therefore, NICE has decided to suspend this appraisal from its work programme. As this appraisal has been referred to the Institute we will continue to monitor any development and will update interested parties if the situation changes.
19 October 2011

Following on from advice received from the manufacturer, the dates for this appraisal will be confirmed once regulatory approval timelines are established.


For further information on how we develop guidance, please see our page about NICE technology appraisal guidance